Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pirarubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.99 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.99 |
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.79 |
| ▸ | HSP90AA1 known ✓ | P07900 | 3/20 | 0.79 |
| ▸ | HSP90AB1 known ✓ | P08238 | 2/20 | 0.79 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.78 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.78 |
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.78 |
| ▸ | NR3C1 known ✓ | P04150 | 2/20 | 0.78 |
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.78 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.78 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.78 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.78 |
| ▸ | TOP1 known ✓ | P11387 | 1/20 | 0.78 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.78 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.78 |
| ▸ | TOP2B known ✓ | Q02880 | 1/20 | 0.78 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.78 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.78 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pirarubicin SCHEMBL29462366 | 1.00 | MEN1 (0.99) | MEN1KMT2ABLMPTGS1HTT | |
| Pirarubicin SCHEMBL31238420 | 1.00 | MEN1 (0.99) | MEN1KMT2ABLMPTGS1HTT | |
| Pirarubicin SCHEMBL29350487 | 1.00 | MEN1 (0.99) | MEN1KMT2ABLMPTGS1HTT | |
| Pirarubicin SCHEMBL28226063 | 1.00 | MEN1 (0.99) | MEN1KMT2ABLMPTGS1HTT | |
| Pirarubicin SCHEMBL8323 | 0.99 | MEN1 (1.00) | MEN1KMT2ABLMPTGS1HTT | |
| Pirarubicin SCHEMBL15472856 | 0.99 | MEN1 (1.00) | MEN1KMT2ABLMPTGS1HTT | |
| Pirarubicin SCHEMBL12257450 | 0.99 | MEN1 (1.00) | MEN1KMT2ABLMPTGS1HTT | |
| Pirarubicin SCHEMBL31499425 | 0.99 | MEN1 (1.00) | MEN1KMT2ABLMPTGS1HTT | |
| Pirarubicin SCHEMBL8324 | 0.99 | MEN1 (1.00) | MEN1KMT2ABLMPTGS1HTT | |
| Pirarubicin SCHEMBL6314144 | 0.99 | MEN1 (1.00) | MEN1KMT2ABLMPTGS1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025074178-A1 | METHODS FOR PREPARING POLYMERIC DYES WITH DRUG CONJUGATES | Sony Group Corporation (JP) | 2025-04-10 | — | — | WO | claimed |
| US-20240398841-A1 | BLADDER PERFUSION PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | INNOBM PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | claimed |
| CN-114681612-B | Bladder perfusion medicine and preparation method and application thereof | 苏州百迈生物医药有限公司 | 2024-10-25 | — | — | CN | claimed |
| CN-118638274-A | Polyvinyl alcohol microsphere and preparation method and application thereof | 湖南埃普特医疗器械有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-117563019-A | Embolic microemulsion particle with developing function and preparation method and application thereof | 南方科技大学 | 2024-02-20 | — | — | CN | claimed |
| EP-4257121-A1 | BLADDER PERFUSION PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Innobm Pharmaceuticals Co., Ltd. (CN) | 2023-10-11 | — | — | EP | claimed |
| CN-116710106-A | Bladder perfusion pharmaceutical composition and preparation method and application thereof | 苏州百迈生物医药有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-114366723-B | Microsphere containing pirarubicin hydrochloride and preparation method and application thereof | 珠海麦得发生物科技股份有限公司 | 2023-07-07 | — | — | CN | claimed |
| US-20230149466-A1 | IMMUNOTHERAPEUTIC METHODS AND COMPOSITIONS FOR TARGETING CANCER FIBROBLASTS | FIGENE, LLC | 2023-05-18 | — | — | US | claimed |
| EP-4142753-A1 | IMMUNOTHERAPEUTIC METHODS AND COMPOSITIONS FOR TARGETING CANCER FIBROBLASTS | Figene, LLC (US) | 2023-03-08 | — | — | EP | claimed |
| CN-101879144-A | Pirarubicin or pirarubicin hydrochloride liposome freeze-drying agent and preparation method thereof | YIMING WANG | 2010-11-10 | — | — | CN | claimed |
| US-20100173862-A1 | INJECTABLE, INJECTION SOLUTION, AND INJECTION KIT PREPARATION | MEIJI SEIKA KAISHA, LTD. (JP) | 2010-07-08 | — | — | US | claimed |
| EP-2184066-A1 | INJECTION, INJECTION SOLUTION AND INJECTION KIT PREPARATION | Meiji Seika Kaisha Ltd. (JP) | 2010-05-12 | — | — | EP | claimed |
| US-20100099639-A1 | W/O/W EMULSION COMPOSITION | CONTROLLED LIPO TECHS, INC. (JP) | 2010-04-22 | — | — | US | claimed |
| US-20100015249-A1 | Antitumor agent containing 6'-amidino-2'-naphthyl 4-guanidinobenzoate or salt thereof | TORII PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | claimed |
| EP-2077106-A1 | W/O/W EMULSION COMPOSITION | Controlled Lipo Techs, Inc. (JP) | 2009-07-08 | — | — | EP | claimed |
| US-20090136577-A1 | Intestinal Absorptive Anti-Tumor Agent | KABUSHIKI KAISHA SANGI (JP) | 2009-05-28 | — | — | US | claimed |
| EP-1911449-A1 | ANTI-TUMOR AGENT COMPRISING 6'-AMIDINO-2'-NAPHTHYL4- GUANIDINOBENZOATE OR SALT THEREOF | TORII PHARMACEUTICAL CO., LTD. (JP) | 2008-04-16 | — | — | EP | claimed |
| EP-1872798-A1 | INTESTINAL ABSORPTIVE ANTI-TUMOR AGENT | KABUSHIKI KAISHA SANGI (JP) | 2008-01-02 | — | — | EP | claimed |
| EP-0608546-A2 | Glia activating factor (GAF), antibodies against it and their uses | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099639-A1 | W/O/W EMULSION COMPOSITION | PLA2G2C, OSTC, LIPA | PTGS1 2320/4885HDAC6 3520/4885TOP2A 1918/4885 |
| US-20240398841-A1 | BLADDER PERFUSION PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | BAD, BPHL, HASPIN | PTGS1 26/4885HDAC6 2259/4885TOP2A 4136/4885 |
| US-20100015249-A1 | Antitumor agent containing 6'-amidino-2'-naphthyl 4-guanidinobenzoate or salt thereof | FUT5, FUT6, FUT4 | PTGS1 1824/4885HDAC6 73/4885TOP2A 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.